Medtronic, Inc. has acquired New Jersey-based TYRX, Inc., often covered on our site, mainly because of its novel implantable combination antibiotic drug and implanted medical devices. The all-cash transaction includes an initial payment of $160 million plus potential earn-out and performance based milestone payments.
TYRX’s product offerings include the recently FDA cleared AIGISRx® R Fully Resorbable Antibacterial Envelope, designed to reduce surgical site infections associated with Cardiac Implantable Electronic Devices (CIEDs), and the AIGISRx® N Antibacterial Envelope, for use with spinal cord neuromostimulators.
Medtronic points to this acquisition supporting its expansion to include broader healthcare services and solutions, and this is certainly a device that is likely to squeeze a few extra dollars out of a variety of implantation procedures.
“While the risk of infection from an implanted pacemaker or defibrillator is low for most patients, repeated operative procedures after the initial device implant are associated with a substantial incremental risk of infection. This is estimated to cost the U.S. healthcare system more than $1 billion per year,” said Pat Mackin, president of the Cardiac Rhythm Disease Management business and senior vice president at Medtronic. “TYRX has developed an innovative, proven technology to reduce infection risk, making the procedure safer for patients and removing significant costs from the healthcare system.”
“We look forward to joining Medtronic as part of a combined portfolio that can positively impact outcomes for patients by reducing implant-related infections, and bring value to our customers,” said Robert White, president and chief executive officer of TYRX.
Source: Medtronic, Inc.